US Patent

US10322117 — Compositions for the treatment of hypertension

Formulation · Assigned to George Institute for Global Health · Expires 2038-01-23 · 12y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions that combine an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker for treating hypertension.

USPTO Abstract

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Drugs covered by this patent

Caduet (Amlodipine Besylate) · Pfizer Inc.

Patent Metadata

Patent number: US10322117
Jurisdiction: US
Classification: Formulation
Expires: 2038-01-23
Drug substance claim: No
Drug product claim: Yes
Assignee: George Institute for Global Health
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.